311 related articles for article (PubMed ID: 31420851)
1. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
2. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
[TBL] [Abstract][Full Text] [Related]
3. Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.
Sahni JM; Gayle SS; Webb BM; Weber-Bonk KL; Seachrist DD; Singh S; Sizemore ST; Restrepo NA; Bebek G; Scacheri PC; Varadan V; Summers MK; Keri RA
Cancer Res; 2017 Oct; 77(19):5395-5408. PubMed ID: 28807940
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
5. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
6. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
7. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
10. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
11. Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.
Li CY; Miao KL; Chen Y; Liu LY; Zhao GB; Lin MH; Jiang C
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6008-6014. PubMed ID: 30280784
[TBL] [Abstract][Full Text] [Related]
12. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
Yi M; Peng C; Xia B; Gan L
Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
14. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G
EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544
[TBL] [Abstract][Full Text] [Related]
15. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
16. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
17. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
Liu T; Sun H; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y; Sun B
Mol Cancer Ther; 2017 Jul; 16(7):1377-1388. PubMed ID: 28416606
[TBL] [Abstract][Full Text] [Related]
18. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Ge JY; Shu S; Kwon M; Jovanović B; Murphy K; Gulvady A; Fassl A; Trinh A; Kuang Y; Heavey GA; Luoma A; Paweletz C; Thorner AR; Wucherpfennig KW; Qi J; Brown M; Sicinski P; McDonald TO; Pellman D; Michor F; Polyak K
Nat Commun; 2020 May; 11(1):2350. PubMed ID: 32393766
[TBL] [Abstract][Full Text] [Related]
20. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
